Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $61.44.

Several brokerages recently weighed in on HALO. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a research note on Monday, October 7th.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $52.80 on Monday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a fifty day simple moving average of $50.14 and a 200-day simple moving average of $54.02. The stock has a market cap of $6.72 billion, a P/E ratio of 17.48, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. First Hawaiian Bank raised its holdings in Halozyme Therapeutics by 56.2% in the fourth quarter. First Hawaiian Bank now owns 57,550 shares of the biopharmaceutical company’s stock valued at $2,751,000 after acquiring an additional 20,700 shares in the last quarter. Oliver Luxxe Assets LLC raised its stake in shares of Halozyme Therapeutics by 5.6% in the 4th quarter. Oliver Luxxe Assets LLC now owns 29,325 shares of the biopharmaceutical company’s stock valued at $1,402,000 after purchasing an additional 1,555 shares in the last quarter. Everence Capital Management Inc. acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $244,000. Retirement Systems of Alabama increased its holdings in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the last quarter. Finally, Castellan Group raised its stake in Halozyme Therapeutics by 4.5% during the third quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock valued at $6,514,000 after buying an additional 4,876 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.